A new research paper was published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled “AI-driven toolset for IPF ...
Our findings establish novel connections between aging biology and IPF pathogenesis while demonstrating the potential of AI-guided approaches in ...
Strategies that combine ferroptosis inhibition with established antifibrotics could ultimately move treatment from slowing progression to truly reversing fibrosis, new research suggests. Despite ...
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced a poster ...
Patients with acute exacerbations of idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) face a high risk of morbidity and mortality and require careful, expert management, ...
Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic (VEXAS) syndrome is a newly identified disorder caused by an ...
Discover Quince Therapeutics’ breakthrough drug-delivery platform aiming to safely treat rare diseases with encapsulated steroids.
Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth ...
BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); ...
Researchers at the University of Calgary studying a lethal lung disease called pulmonary fibrosis have found that neurons ...
A research group from the National Cancer Research Center (CNIO) has found that an alteration in the POT1 gene prevents lung tissue from regenerating, which over time makes breathing difficult. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback